Britain’s biotech firms now have a code of conduct designed to prevent them
from overhyping the progress of experimental drugs. Published this week by the
BioIndustry Association (BIA), the code was drafted in the wake of a damaging
scandal last year
(This Week, 4 July 1998, p 20).
From now on, companies must
have their scientific and clinical progress audited by external experts. Failure
to comply could mean expulsion from the BIA.
More from Â鶹´«Ã½
Explore the latest news, articles and features
Popular articles
Trending Â鶹´«Ã½ articles
1
We've found a mysterious substance on Titan and Pluto
2
Faecal transplant makes the brains of old mice act young again
3
The secrets to keeping your brain sharp in old age
4
A quantum state that lasts forever may finally be within our grasp
5
Can prebiotics, probiotics or postbiotics help your ageing microbiome?
6
Bioplastic habitats on Mars could be built from algae
7
Cervical cancer deaths have plummeted thanks to HPV vaccine
8
Remarkable fossils rewrite the story of how animals conquered the land
9
Autism may have two distinct subtypes that vary by brain activity
10
Chilling the body with drugs could limit brain damage from stroke
